Lubomir Nechev, PhD

Senior Vice President CMC Development at Alnylam Pharmaceuticals, Inc.

Speaker

Lubomir Nechev, Ph.D. is the Chief CMC Officer of Alnylam Pharmaceuticals. Dr Nechev is oneof the pioneers in the CMC aspects of RNAi therapeutics. He has worked at RibozymePharmaceuticals (RPI), the Nucleic Acids Synthesis unit of Transgenomic, Inc., and has joinedAlnylam in March 2004. In the last 20 years, Dr. Nechev has led the development andimplementation of the CMC strategy for siRNA therapeutics used in five approved products –ONPATTRO®, GIVLAARI®, OXLUMO®, Leqvio®(Novartis), and AMVUTTRA™. The first of them(ONPATTRO®) is also the first approved lipid nanoparticle (LNP) formulated siRNA and thesecond one (GIVLAARI®) is the first approved GalNAc‐conjugated siRNA.Dr. Nechev received his Ph.D. degree in Organic Chemistry from St. Kl. Ohridski University,Sofia, Bulgaria and completed his post‐doctoral training at the Department of Chemistry andCenter in Molecular Toxicology at Vanderbilt University, Nashville, Tennessee.